Medical device labeling: You need to design it, too

When designing and developing a medical device, companies often consider labeling down the road, but they shouldn’t, says Michael Drues, a regulatory consultant based outside Boston.

Labeling can involve a variety of ways a medtech company markets a product. What Drues calls high-level labeling – indications for use, intended use and label claims – drives to the heart of a company’s regulatory strategy.

“High-level labeling will directly impact your regulatory strategy and your pathway to market,” Drues said. (See Drues moderate a regulatory panel at DeviceTalks Boston on Oct. 2.)

Depending on the high-level labeling, the same product could be a wellness device not regulated as a medical device – or a device requiring a 510(k), de novo or PMA. Companies also need to balance out how the labeling will affect winning reimbursement from public and private healthcare payers – not to mention product liability exposure.

The result is that medical device creators need to design their labels like they design their devices, according to Drues, who is president of Vascular Sciences and has worked with both medical device companies and FDA. “To me, design is design.”

Listen to Drues discuss the importance of label design – as well as his four-step design process.

(See Drues moderate a regulatory panel at DeviceTalks Boston on Oct. 2.)

[Want to stay more on top of MDO content? Subscribe to our weekly e-newsletter.]

Theranos whistleblower Tyler Shultz to participate in keynote interview at DeviceTalks Boston At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos. Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston. REGISTER NOW